AU2024321098A1 — Sirna for inhibiting dgat2 gene expression, sirna conjugate or prodrug and pharmaceutical composition thereof, and use thereof
Assigned to Beijing Foyou Pharma Co Ltd · Expires 2026-03-19 · 0y expired
What this patent protects
Provided are an siRNA for inhibiting DGAT2 gene expression, an siRNA conjugate and a prodrug thereof, a pharmaceutical composition comprising same, and the use thereof. Each nucleotide in the siRNA is independently a modified or unmodified nucleotide, and the siRNA contains a sen…
USPTO Abstract
Provided are an siRNA for inhibiting DGAT2 gene expression, an siRNA conjugate and a prodrug thereof, a pharmaceutical composition comprising same, and the use thereof. Each nucleotide in the siRNA is independently a modified or unmodified nucleotide, and the siRNA contains a sense strand and an antisense strand. The siRNA, the conjugate and the prodrug and pharmaceutical composition thereof can effectively treat and/or prevent diseases associated with DGAT2 gene overexpression.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.